Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 8:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 235 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Anticoagulant drugs Clear all
Completed Phase 1 Interventional

Safety and Dosing Evaluation of REG1 Anticoagulation System

NCT00113997
View directory record Official record
Conditions
Healthy
Interventions
REG1
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 13, 2026, 8:34 PM EDT
Completed Phase 3 Interventional

Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients

NCT00135876
View directory record Official record
Conditions
Venous Thromboembolism, Brain Tumors
Interventions
dalteparin
Drug
Lead sponsor
Ontario Clinical Oncology Group (OCOG)
Other
Eligibility
18 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
3
States / cities
Evanston, Illinois • Detroit, Michigan • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2007 · Synced Oct 13, 2026, 8:34 PM EDT
Recruiting Not applicable Interventional

DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis

NCT05701917
View directory record Official record
Conditions
Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome
Interventions
ClotTriever System, Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.
Device · Drug
Lead sponsor
Inari Medical
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
48
States / cities
Scottsdale, Arizona • Tucson, Arizona • Orange, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 13, 2026, 8:34 PM EDT
Withdrawn Not applicable Interventional

Efficacy of Methods to Treat Multiple Gingival Recession Defects

NCT03124329
View directory record Official record
Conditions
Gingival Recession
Interventions
Coronally Advanced Flap, Intrasulcular Tunneling, Vestibular Incision Subperiosteal Tunnel Access (VISTA), Leukocyte-Platelet Rich Fibrin (L-PRF)
Procedure · Biological · Device
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 13, 2026, 8:34 PM EDT
Completed Phase 3 Interventional Results available

An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N (Kcentra) Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Subjects Requiring an Urgent Surgical Procedure

NCT00803101
View directory record Official record
Conditions
Reversal of Coagulopathy
Interventions
Beriplex® P/N (Kcentra), Fresh frozen plasma
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
16
States / cities
Newark, Delaware • Lexington, Kentucky • Boston, Massachusetts + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Oct 13, 2026, 8:34 PM EDT
Completed Phase 4 Interventional

Clinical Decision Rule Validation Study to Predict Low Recurrent Risk in Patients With Unprovoked Venous Thromboembolism

NCT00967304
View directory record Official record
Conditions
Idiopathic Venous Thromboembolism
Interventions
Application of the"Men continue and HER DOO2" rule
Other
Lead sponsor
Ottawa Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
2,779 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
3
States / cities
Santa Monica, California • Rockport, Maine • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Oct 13, 2026, 8:34 PM EDT
Completed Phase 3 Interventional Results available

Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)

NCT02798471
View directory record Official record
Conditions
Venous Thromboembolism (VTE), Pulmonary Embolism, Deep Vein Thrombosis (DVT)
Interventions
Edoxaban, Standard of Care
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
1 Day to 17 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
22
States / cities
Tucson, Arizona • Los Angeles, California • Stanford, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 13, 2026, 8:34 PM EDT
Completed Not applicable Interventional

Get With the Guidelines in ED Patients With Heart Failure

NCT02519283
View directory record Official record
Conditions
Heart Failure
Interventions
GUIDED-HF, Standard of Care
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
21 Years and older
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
15
States / cities
Atlanta, Georgia • Indianapolis, Indiana • Iowa City, Iowa + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2020 · Synced Oct 13, 2026, 8:34 PM EDT
Completed No phase listed Observational

Replication of the RECORD1 Anticoagulant Trial in Healthcare Claims Data

NCT05083455
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolus
Interventions
Rivaroxaban, Enoxaparin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 120 Years
Enrollment
89,215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 13, 2026, 8:34 PM EDT
Active, not recruiting No phase listed Observational

Oral Health In Cirrhosis of the Liver (ORACLE)

NCT06052150
View directory record Official record
Conditions
Cirrhosis, Periodontal Diseases
Interventions
Dental exam and periodontal cleaning if needed
Procedure
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 13, 2026, 8:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Supporting Use of AC Through Provider Profiling of Oral AC Therapy for AF

NCT03583008
View directory record Official record
Conditions
Atrial Fibrillation, Prescribing Practices, Anticoagulants
Interventions
Anticoagulation (AC) Intervention--Academic Detailing, Anticoagulation (AC) Intervention--Prescribing Practices
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Oct 13, 2026, 8:34 PM EDT
Completed Phase 3 Interventional Results available

Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)

NCT02345850
View directory record Official record
Conditions
Acute Leukemia, Myelodysplasia
Interventions
Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate, Mobilized CD34-selected Peripheral Blood Stem Cell graft, Unmanipulated Bone Marrow Graft with Cyclophosphamide, Cyclophosphamide, Tacrolimus, Methotrexate
Procedure · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
1 Year to 65 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
28
States / cities
Duarte, California • Stanford, California • Gainesville, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Oct 13, 2026, 8:34 PM EDT
Terminated Not applicable Interventional

Syntrillo Telehealth Stroke Risk Reduction Study

NCT07124728
View directory record Official record
Conditions
Hypertension, Hypertension (HTN), Stroke Prevention, Cardiovascular Risk Factor
Interventions
Technology-enabled Telehealth Care Plan, Blood Pressure Monitoring Device, Tenovi Smart Pillbox, Wearable Activity Trackers (Fitbit or Apple Watch), Healthie EHR, Secure Messaging Platforms (TigerConnect, Weave, AirCall), Antihypertensive Medication Management, Statin Medication Management, Antiplatelet or Anticoagulant Therapy, Laboratory Blood Test Collection
Behavioral · Device · Other + 2 more
Lead sponsor
Syntrillo, Inc
Other
Eligibility
30 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 13, 2026, 8:34 PM EDT
Completed Phase 2 Interventional

Anticoagulation With rNAPc2 to Eliminate MACE/TIMI 32

NCT00116012
View directory record Official record
Conditions
Coronary Disease
Interventions
rNAPc2
Drug
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 29, 2006 · Synced Oct 13, 2026, 8:34 PM EDT
Completed Phase 4 Interventional Results available

Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI

NCT04483583
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Ticagrelor 60mg, Clopidogrel
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 13, 2026, 8:34 PM EDT
Completed No phase listed Observational

Replication of the ROCKET-AF Anticoagulant Trial in Healthcare Claims Data

NCT04593056
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Warfarin, Rivaroxaban
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
102,636 participants
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 13, 2026, 8:34 PM EDT
Completed No phase listed Observational

Benchmarking an Oral Anticoagulant Treatment Rate in Patients With Nonvalvular Atrial Fibrillation

NCT02919982
View directory record Official record
Conditions
Nonvalvular Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Baim Institute for Clinical Research
Other
Eligibility
18 Years and older
Enrollment
817 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
21
States / cities
Anchorage, Alaska • Orange, California • Clearwater, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Oct 13, 2026, 8:34 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 3 of 4)

NCT03551730
View directory record Official record
Conditions
Healthy Volunteers
Interventions
PRT064445/Enoxaparin, Placebo/Enoxaparin, Placebo
Combination Product · Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Oct 13, 2026, 8:34 PM EDT
Recruiting Not applicable Interventional

Carotid Implants for PreveNtion of STrokE ReCurrEnce From Large Vessel Occlusion in Atrial Fibrillation Patients Treated With Oral Anticoagulation

NCT05723926
View directory record Official record
Conditions
Atrial Fibrillation, Oral Anticoagulation, Stroke, Implant
Interventions
Vine Filter
Device
Lead sponsor
Javelin Medical
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
Rockford, Illinois • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 13, 2026, 8:34 PM EDT
Recruiting Phase 4 Interventional

International Care Bundle Evaluation in Cerebral Hemorrhage Research

NCT06429332
View directory record Official record
Conditions
Intracerebral Hemorrhage, Intracerebral Haemorrhage, Intraventricular Hemorrhage, Stroke, Cerebrovascular Disease
Interventions
Reversal of Oral anticoagulation within 30 minutes, Early intensive blood pressure lowering, Treatment of pyrexia, Hyperglycemia treatment, Do-not-resuscitate (DNR) or withdrawal of care, Referral to Intensive Care, Referral to Neurosurgery, Repeat brain imaging, Standard care
Other · Diagnostic Test
Lead sponsor
Region Skane
Other
Eligibility
18 Years and older
Enrollment
3,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 13, 2026, 8:34 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation

NCT02889562
View directory record Official record
Conditions
Coronary Artery Bypass Grafting, Postoperative Atrial Fibrilation, Stroke, Systemic Embolism, Deep Venous Thrombosis
Interventions
Apixaban, Warfarin
Drug
Lead sponsor
Sanford Health
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 13, 2026, 8:34 PM EDT
Terminated Phase 3 Interventional Results available

Ethanol Locks for the Treatment of Central Venous Line Infections

NCT00680459
View directory record Official record
Conditions
Bloodstream Infection
Interventions
70% ethanol, heparin flush solution
Drug
Lead sponsor
Baystate Medical Center
Other
Eligibility
6 Months to 23 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Oct 13, 2026, 8:34 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation

NCT00504556
View directory record Official record
Conditions
Atrial Fibrillation, Thromboembolism
Interventions
Edoxaban (DU-176b), warfarin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
22
States / cities
Huntsville, Alabama • Anaheim, California • Beverly Hills, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 13, 2026, 8:34 PM EDT
Completed Not applicable Interventional Results available

Strategies for Anticoagulation During Venovenous ECMO

NCT04997265
View directory record Official record
Conditions
Acute Hypoxemic Respiratory Failure, Anticoagulant-induced Bleeding, Thromboembolism
Interventions
Low intensity anticoagulation, Moderate Intensity Anticoagulation
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 13, 2026, 8:34 PM EDT